On Sunday, AstraZeneca PLC said that its clinical research depicted that experimental anti-clotting drug Brilinta made by it needed no generic examination, so as to ascertain if it worked properly or not, which is opposite to the blockbuster heart medicine, Plavix, which is made by Sanofi-Aventis.

While giving a statement, AstraZeneca said that that a thorough study illustrated that using Brilinta, which is better recognized by the name ticagrelor, to patients with severe coronary syndrome did not make it necessary to undergo evaluation that is taken to be essential, so as to avert poor reaction of the drug while a patient is being treated with Plavix.

Conditions that are a result of low blood flow to heart muscle, which ranges from chest pain to cardiac arrest, have an umbrella term ACS.

The Brilinta trial, with 18,624 patients, named A Study of PLATelet Inhibition and Patient Outcomes, received a backing from the U. K.-based AstraZeneca.

PLATO depicted Brilinta helped in reducing the heart attacks of various combinations, strokes and death due to cardiovascular causes in comparison with Plavix.

Researchers said that the vantage seen came without a hike in severe bleeding complexities.

Brilinta has yet not been brought out in the market, but an approval is expected from U. S. FDA on 16th September.